Ligand (LGND) | Stock Overview & Key Data
Ligand Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $173.81 on October 1, 2018
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Ligand LGND | 2.23B Mid-cap | 7.69% | 11.80% | 17.86% | 15.17% | 12.89% | 15.80% | 95.22% | 50.27% |
| Vertex VRTX | 114.06B Large-cap | 4.80% | 7.35% | -0.69% | 16.95% | 18.04% | -4.58% | 59.25% | 58.34% |
| Regeneron REGN | 59.14B Large-cap | 0.88% | 6.76% | -4.19% | -20.71% | -22.74% | -50.21% | -9.84% | -14.95% |
| Blueprint Medicines BPMC | 8.30B Mid-cap | 0.27% | 0.45% | 56.67% | 47.03% | 47.42% | 9.02% | 139.78% | 65.31% |
| Roivant Sciences ROIV | 7.38B Mid-cap | 2.28% | 1.26% | 13.45% | 5.55% | -7.12% | -4.32% | 154.33% | 9.48% |
| Bio-Techne TECH | 7.92B Mid-cap | -1.11% | 5.43% | -2.74% | -28.26% | -26.43% | -31.86% | -38.81% | -24.68% |
Ownership & Short Interest
Ligand Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Ligand would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
What is LGND's 52-week high and low?
In the last 52 weeks, Ligand reached a high of $129.90 (on November 7, 2024) and a low of $87.28 (on July 9, 2024).
What is the market cap and P/E ratio for LGND?
Curious about Ligand's size and valuation? Its market capitalization stands at 2.23B. When it comes to valuation, the P/E ratio (trailing twelve months) is 46.27, and the forward P/E (looking ahead) is 19.31.
Does LGND pay dividends? If so, what's the yield?
As for dividends, Ligand isn't currently offering a significant yield, or that specific data isn't available right now.
Who are Ligand's main competitors or similar companies to consider before investing?
When looking at Ligand, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
| Company | Mkt Cap | Sector | Industry | 1Y Return | 3Y Return |
|---|---|---|---|---|---|
| Vertex VRTX | 114.06B | Healthcare | Biotechnology | -4.58% | 59.25% |
| Regeneron REGN | 59.14B | Healthcare | Biotechnology | -50.21% | -9.84% |
| Blueprint Medicines BPMC | 8.30B | Healthcare | Biotechnology | 9.02% | 139.78% |
| Roivant Sciences ROIV | 7.38B | Healthcare | Biotechnology | -4.32% | 154.33% |
| Bio-Techne TECH | 7.92B | Healthcare | Biotechnology | -31.86% | -38.81% |
For a more comprehensive list, please see the Peer Performance Comparison table on this page.
What are the key financial health indicators for Ligand Pharmaceuticals Inc.? (e.g., ROE, Debt/Equity)
To get a sense of Ligand's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -16.56%, the Debt to Equity ratio from the most recent quarter is 0.56, and its Gross Profit Margin stands at 89.30%.
What is the recent revenue and earnings growth for LGND?
Looking at Ligand's growth, its revenue over the trailing twelve months (TTM) was $181M. Compared to the same quarter last year (YoY), quarterly revenue grew by 46.30%, and quarterly earnings saw a YoY growth of 46.34%.
How much of LGND stock is held by insiders and institutions?
Wondering who owns Ligand stock? Company insiders (like executives and directors) hold about 2.29% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 99.82%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.